BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 14571691)

  • 1. Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice.
    Xu L; Eiseman JL; Egorin MJ; D'Argenio DZ
    J Pharmacokinet Pharmacodyn; 2003 Jun; 30(3):185-219. PubMed ID: 14571691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
    Egorin MJ; Zuhowski EG; Rosen DM; Sentz DL; Covey JM; Eiseman JL
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):291-302. PubMed ID: 11345645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations.
    Egorin MJ; Rosen DM; Wolff JH; Callery PS; Musser SM; Eiseman JL
    Cancer Res; 1998 Jun; 58(11):2385-96. PubMed ID: 9622079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies.
    Chen X; Bies RR; Ramanathan RK; Zuhowski EG; Trump DL; Egorin MJ
    Cancer Chemother Pharmacol; 2005 Mar; 55(3):237-43. PubMed ID: 15503027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.
    Ramanathan RK; Trump DL; Eiseman JL; Belani CP; Agarwala SS; Zuhowski EG; Lan J; Potter DM; Ivy SP; Ramalingam S; Brufsky AM; Wong MK; Tutchko S; Egorin MJ
    Clin Cancer Res; 2005 May; 11(9):3385-91. PubMed ID: 15867239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biliary excretion of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) and metabolites by Fischer 344 rats.
    Musser SM; Egorin MJ; Zuhowski EG; Hamburger DR; Parise RA; Covey JM; White KD; Eiseman JL
    Cancer Chemother Pharmacol; 2003 Aug; 52(2):139-46. PubMed ID: 12761648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.
    Chung YL; Troy H; Banerji U; Jackson LE; Walton MI; Stubbs M; Griffiths JR; Judson IR; Leach MO; Workman P; Ronen SM
    J Natl Cancer Inst; 2003 Nov; 95(21):1624-33. PubMed ID: 14600095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.
    Kelland LR; Sharp SY; Rogers PM; Myers TG; Workman P
    J Natl Cancer Inst; 1999 Nov; 91(22):1940-9. PubMed ID: 10564678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
    Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma.
    Johnston JS; Phelps MA; Blum KA; Blum W; Grever MR; Farley KL; Dalton JT
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Aug; 871(1):15-21. PubMed ID: 18635408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts.
    Eiseman JL; Lan J; Lagattuta TF; Hamburger DR; Joseph E; Covey JM; Egorin MJ
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):21-32. PubMed ID: 15338192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action.
    Guo W; Reigan P; Siegel D; Ross D
    Drug Metab Dispos; 2008 Oct; 36(10):2050-7. PubMed ID: 18635747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
    Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
    Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization.
    Russell JS; Burgan W; Oswald KA; Camphausen K; Tofilon PJ
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3749-55. PubMed ID: 14506167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
    Bisht KS; Bradbury CM; Mattson D; Kaushal A; Sowers A; Markovina S; Ortiz KL; Sieck LK; Isaacs JS; Brechbiel MW; Mitchell JB; Neckers LM; Gius D
    Cancer Res; 2003 Dec; 63(24):8984-95. PubMed ID: 14695217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
    Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models.
    Burger AM; Fiebig HH; Stinson SF; Sausville EA
    Anticancer Drugs; 2004 Apr; 15(4):377-87. PubMed ID: 15057143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
    Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
    Cancer Res; 2005 Nov; 65(21):10006-15. PubMed ID: 16267026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
    Schulte TW; Neckers LM
    Cancer Chemother Pharmacol; 1998; 42(4):273-9. PubMed ID: 9744771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53-mediated apoptosis in head and neck cancer.
    Roh JL; Kim EH; Park HB; Park JY
    Cell Death Dis; 2013 Dec; 4(12):e956. PubMed ID: 24336076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.